Wells Fargo & Company Has Lowered Expectations for Autolus Therapeutics (NASDAQ:AUTL) Stock Price

Autolus Therapeutics (NASDAQ:AUTL) had its price objective reduced by Wells Fargo & Company from $8.00 to $6.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target points to a potential upside of 251.91% from the stock’s previous close.

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Autolus Therapeutics has a consensus rating of “Buy” and an average price target of $9.52.

Autolus Therapeutics Trading Up 1.8 %

Shares of AUTL traded up $0.03 during trading hours on Friday, reaching $1.71. 1,458,467 shares of the stock traded hands, compared to its average volume of 1,374,630. Autolus Therapeutics has a 52 week low of $1.57 and a 52 week high of $6.60. The company has a market cap of $453.69 million, a price-to-earnings ratio of -1.41 and a beta of 2.07. The stock has a fifty day simple moving average of $2.03 and a 200 day simple moving average of $2.93.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12. The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $2.98 million. Analysts predict that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Several hedge funds have recently made changes to their positions in the company. FMR LLC increased its holdings in Autolus Therapeutics by 44.6% in the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after acquiring an additional 5,478,706 shares during the last quarter. Capstone Investment Advisors LLC bought a new position in Autolus Therapeutics during the third quarter worth about $51,000. Bellevue Group AG increased its stake in shares of Autolus Therapeutics by 27.7% in the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after purchasing an additional 9,000 shares in the last quarter. Erste Asset Management GmbH bought a new stake in shares of Autolus Therapeutics in the third quarter valued at approximately $708,000. Finally, HighVista Strategies LLC raised its position in shares of Autolus Therapeutics by 2.7% in the third quarter. HighVista Strategies LLC now owns 533,024 shares of the company’s stock valued at $1,935,000 after purchasing an additional 14,204 shares during the period. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.